Last reviewed · How we verify
Exacyl®
Exacyl (tranexamic acid) inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.
Exacyl (tranexamic acid) inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding. Used for Prevention and treatment of hemorrhage in surgical patients, Management of heavy menstrual bleeding, Hemophilia and other bleeding disorders.
At a glance
| Generic name | Exacyl® |
|---|---|
| Also known as | Tranexamic acid |
| Sponsor | University Hospital, Brest |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are key enzymes in the fibrinolytic cascade responsible for breaking down blood clots. By preventing the conversion of plasminogen to plasmin, the drug stabilizes fibrin clots and reduces fibrin degradation, making it effective for controlling bleeding in various clinical settings.
Approved indications
- Prevention and treatment of hemorrhage in surgical patients
- Management of heavy menstrual bleeding
- Hemophilia and other bleeding disorders
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Hypotension
- Visual disturbances
Key clinical trials
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) (PHASE3)
- Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2) (NA)
- Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment. (NA)
- Effectiveness of Tranexamic Acid in Reducing Blood Loss During Femoral Nail Surgery (PHASE4)
- TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia (PHASE3)
- Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma (PHASE4)
- Tranexamic Acid to Reduce Blood Loss in Spine Surgery (PHASE2, PHASE3)
- Perioperative Management in Gynaecological Carcinoma Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exacyl® CI brief — competitive landscape report
- Exacyl® updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI